Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Metzelder, SK; Schroeder, T; Finck, A; Scholl, S; Fey, M; Götze, K; Linn, YC; Kröger, M; Reiter, A; Salih, HR; Heinicke, T; Stuhlmann, R; Müller, L; Giagounidis, A; Meyer, RG; Brugger, W; Vöhringer, M; Dreger, P; Mori, M; Basara, N; Schäfer-Eckart, K; Schultheis, B; Baldus, C; Neubauer, A; Burchert, A 
Titel:
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. 
Abstract:
Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. To address these questions, we evaluated sorafenib monotherapy in 65 FLT3-ITD AML patients treated at 23 centers. All but two patients had relapsed or were chemotherapy-refractory af...    »
 
Zeitschriftentitel:
Leukemia 
Jahr:
2012 
Band / Volume:
26 
Heft / Issue:
11 
Seitenangaben Beitrag:
2353-9 
Sprache:
eng 
Print-ISSN:
0887-6924 
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik